Positions

Overview

  • Introduction:

    Dr. Bal is a malignant hematologist caring for patients with plasma cell disorders with special interest in Light chain (AL) Amyloidosis and MultipleMyeloma. She is additionally sub-specialty fellowship trained to perform stem cell
    transplantation and cellular therapies such as chimeric antigen receptor (CAR) T cell therapies.

    Clinical Interests:

    Dr. Bal is working with other UAB subspecialty colleagues to start a specialized interdisciplinary program in systemic AL Amyloidosis, the first of its kind in Alabama.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myelomaJournal of Geriatric Oncology.  13:486-492. 2022
    2022 Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research 2022
    2022 Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myelomaAmerican Journal of Hematology.  97:E153-E155. 2022
    2022 Revisiting the impact of immunoglobulin isotypes in multiple myelomaAnnals of Hematology.  101:825-829. 2022
    2022 Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapiesLeukemia.  36:877-880. 2022
    2022 A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patientsBone Marrow Transplantation.  57:295-298. 2022
    2021 Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.Journal of Clinical Oncology.  JCO2101935. 2021
    2021 AL amyloidosis: untangling new therapiesHematology online (ASH).  2021:682-688. 2021
    2021 Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myelomaBritish Journal of Haematology.  195:e113-e116. 2021
    2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantationAmerican Journal of Hematology.  96:E396-E398. 2021
    2021 Autologous stem cell transplantation in the age of ANDROMEDABritish Journal of Haematology.  193:865-866. 2021
    2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationBone Marrow Transplantation.  56:1364-1372. 2021
    2021 Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapyLancet Haematology.  8:e386-e387. 2021
    2021 Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - ReplyJAMA Oncology.  7:635-636. 2021
    2021 New regimens and directions in the management of newly diagnosed multiple myelomaAmerican Journal of Hematology.  96:367-378. 2021
    2021 International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLeukemia.  35:18-30. 2021
    2020 Age is just a number, the wrong numberCancer.  126:5014-5016. 2020
    2020 Solid Organ Transplantation 2020
    2020 Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaBiology of Blood and Marrow Transplantation.  26:1394-1401. 2020
    2020 Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the data 2020
    2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma 2020
    2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observations 2020
    2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisJAMA Oncology.  6:1759-1765. 2020
    2020 Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline ChemoimmunotherapyBiology of Blood and Marrow Transplantation2020
    2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myelomaBritish Journal of Haematology.  186:807-819. 2019
    2019 Lessons learned from checkpoint blockade targeting PD-1 in multiple myelomaCancer Immunology Research.  7:1224-1229. 2019
    2016 The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancerJournal of Surgical Oncology.  114:323-328. 2016
    2015 Myocardial perfusion imaging determination using an appropriate use smartphone applicationJournal of Nuclear Cardiology.  22:66-71. 2015
    2014 Potential of F-18 PET/CT in the Detection of Leptomeningeal Metastasis.Rivista di Neuroradiologia.  27:685-689. 2014
    2011 Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancerNuclear Medicine Communications.  32:52-58. 2011

    Investigator On

  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SUTRO BIOPHARM
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by EUSA PHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Janssen
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Bharati Vidyapeeth University 2012
  • Full Name

  • Susan Bal